<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Press Coverage Blood Cancer

Liso-cel Significantly Improves Outcomes in Second-Line DLBCL

Default sub title

Author Healio | Publish Date December 11, 2021

Second-line lisocabtagene maraleucel more than quadrupled EFS compared with standard therapy for patients with relapsed or refractory large B-cell lymphoma, according to study results presented at ASH Annual Meeting and Exposition.

Comments